Dose reduction of steroid premeditation for paclitaxel: No increase of hypersensitivity reactions

Background: Premeditation with dexamethasone, ranitidine and clemastine is mandatory for patients receiving paclitaxel to avoid hypersensitivity react ions. The proposed dexamethasone dose is 20 mg orally 12 and 6 h prior to p aclitaxel infusion. With this premeditation severe hypersensitivity reactio ns are reduced to 1-2% of the treated patients. Besides this oral schedule a single dose of dexamethasone, 40 mg given i.v., just prior to paclitaxel has been shown to be equally effective. In an attempt to reduce steroid-ind uced side effects, especially for patients receiving weekly paclitaxel prot ocols, we reduced the dexamethasone dose. Patients and Methods: A total of 132 patients were treated on an outpatient basis with paclitaxel-containing protocols. Paclitaxel was given in doses of 135-175 mg/m(2) once every 3 w eeks in 76 patients and/or with 100 mg/m(2) weekly in 70 patients. Dexameth asone premeditation was given in a single dose (40, 20, 10 mg) as an infusi on directly before paclitaxel. Results: 0/46 patients receiving 40 mg dexam ethasone premedication in 235 cycles and 0/48 patients receiving 20 mg dexa methasone premeditation in 186 cycles experienced a severe hypersensitivity reaction. 1/52 patients receiving 10 mg dexamethasone in 480 applications developed a severe hypersensitivity reaction with bronchospasm, hypotension and supraventricular tachycardia shortly after her first paclitaxel infusi on started. Conclusion: No increase of severe hypersensitivity reactions is seen when dexamethasone premeditation is reduced to doses of 20 or even 10 mg prior to paclitaxel infusion.